Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
about
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
P2860
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Daclatasvir + asunaprevir vers ...... ients: an indirect comparison.
@en
type
label
Daclatasvir + asunaprevir vers ...... ients: an indirect comparison.
@en
prefLabel
Daclatasvir + asunaprevir vers ...... ients: an indirect comparison.
@en
P2093
P2860
P356
P1476
Daclatasvir + asunaprevir vers ...... ients: an indirect comparison.
@en
P2093
Elyse Swallow
Fiona McPhee
Gail Wygant
James Signorovitch
P2860
P304
P356
10.2217/CER.15.69
P577
2016-01-21T00:00:00Z